Serono

GnRH antagonist requires fewer injections to prevent premature ovulation

Published in Nursing Home and Elder Business Week, November 14th, 2004

In the first clinical trial to directly compare gonadotropin releasing hormone (GnRH) antagonists, patients using Cetrotide (cetrorelix acetate for injection; manufactured by Serono) required fewer injections compared to patients using Ganirelix Acetate (formerly known as Antagon Injection) to prevent premature ovulation during infertility treatment.

The data were presented on October 29, 2004, at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) by John G. Wilcox, MD, FCOG, assistant clinical professor in the Department of Obstetrics and Gynecology at the University of Southern California School of Medicine and managing partner of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week

Source: Nursing Home and Elder Business Week (2004-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry